Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

NCT05758922 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

GM2 Gangliosidosis
Niemann-Pick Disease, Type C

Interventions

DRUG: AZ-3102 (Dose 1)
DRUG: Placebo
DRUG: AZ-3102 (Dose 2)

Sponsor

Azafaros A.G.